Use a Low-Molecular-Weight Heparin for Most Patients With Cancer-Associated VTE

September 2017

We're getting questions about whether to use a direct oral anticoagulant (DOAC) in patients with cancer-associated thromboembolism.

The role of DOACs (Eliquis, Xarelto, etc) is expanding. Chest guidelines now favor these meds for most patients with venous thromboembolism (VTE)...deep vein thrombosis or pulmonary embolism.

But don't jump to a DOAC first-line to treat or prevent recurrent VTE in cancer patients...due to limited efficacy and safety data.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote